Turing Pharmaceuticals controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2020
Alleged anticompetitive conduct involving Daraprim
The FTC alleged that Vyera and associated parties used anticompetitive practices to maintain Daraprim’s monopoly and prevent generic competition. The matter was resolved through a settlement in 2021.
2015
Daraprim price increase
Turing increased Daraprim’s price from $13.50 to $750 per tablet after acquiring U.S. marketing rights. The decision prompted widespread criticism because the medicine was used to treat potentially serious toxoplasmosis infections.